The Spectra Decoding Platform (SDP) moves discovery through a staged workflow where each library builds on the previous discoveries with analytics guiding every transition from hit to IND compound.

• Natural Product Libraries – Collections of small molecules and short peptides extracted from diverse natural sources, pre-characterized for chemical diversity, physicochemical properties, and inherent biological activity to serve as the foundation for identifying privileged nature-based scaffolds.

• Biologically Derived Libraries – Engineered derivatives generated via synthetic biology to refine initial hits, enhance novelty, and introduce scaffold-informed modifications that improve potency and drug-like properties.

• Synthetic Combinatorial Libraries – Rationally designed libraries built from fragment-based insights and optimized organic scaffolds. Synthetic chemistry expands the accessible chemical space and enables precise tuning of pharmacological and ADME/DMPK profiles.

This stepwise process ensures that each stage informs and strengthens the next, accelerating the transition from hit discovery to optimized drug candidates while reducing development risk. As part of our roadmap, Linker Sciences will launch ready-to-use and bespoke SDP Kits to integrate staged libraries and analytics into turnkey solutions for all stages of drug discovery and development.

Technology Advantages

• Direct measurement of IC₅₀ and selectivity from spectral data.

• No dependence on DNA tags, artificial encodings, or receptor crystal structures.

• Natively compatible with small molecules, short peptides, and non-canonical chemistries.

• Fully integrable with affinity selection, pull-down, and off-DNA validation workflows.

Screening & Coverage

• Comprehensive chemical space libraries spanning natural products, engineered metabolites, and synthetic combinatorial chemistries.

• Compatible with soluble proteins, membrane receptors, multi-protein complexes, and intrinsically disordered regions.

• Disease-agnostic applications spanning oncology, infectious disease, neurology, and beyond.

• Delivered as standardized kits with SOPs, validated protocols, and instrument settings.

• Supports pooled affinity screens, competitive binding assays, and quantitative selectivity profiling.

Development Impact

• Accelerates hit identification, scaffold prioritization, and SAR initiation.

• Shortens early discovery timelines, driving faster progression from hit to IND.

• Expands access to first-in-class and best-in-class opportunities through unique chemical space.

• Integrates smoothly with medicinal chemistry, ADME/DMPK, and preclinical development workflows.